Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Cost of Revenue (2016 - 2025)

Ligand Pharmaceuticals' Cost of Revenue history spans 15 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 5.46% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $14.5 million, up 31.38%, while the annual FY2025 figure was $14.5 million, 31.38% up from the prior year.
  • Cost of Revenue for Q4 2025 was $3.0 million at Ligand Pharmaceuticals, down from $3.8 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $30.6 million in Q2 2021 and bottomed at $1.6 million in Q4 2023.
  • The 5-year median for Cost of Revenue is $3.8 million (2023), against an average of $7.6 million.
  • The largest annual shift saw Cost of Revenue surged 300.22% in 2021 before it crashed 92.41% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $12.0 million in 2021, then soared by 80.36% to $21.6 million in 2022, then plummeted by 92.41% to $1.6 million in 2023, then skyrocketed by 72.88% to $2.8 million in 2024, then rose by 5.46% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Cost of Revenue are $3.0 million (Q4 2025), $3.8 million (Q3 2025), and $2.9 million (Q2 2025).